Subacute combined degeneration of the spinal cord (SACD) is the most severe neurological complication of B12 deficiency and the one where the speed of diagnosis determines the outcome — the pathology is demyelination of: (1) the posterior columns (dorsal columns — responsible for vibration, proprioception, and joint position sense), causing sensory ataxia, positive Romberg test, and falls; and (2) the corticospinal tracts (lateral columns), causing progressive spastic paraparesis with upper motor neurone signs (hyper-reflexia, Babinski positive, clonus). The critical clinical principle: SACD can occur WITHOUT macrocytic anaemia — neurological manifestations of B12 deficiency can precede or occur entirely independently of haematological changes. This means that a patient with a normal full blood count, and even a normal-range serum B12 (if borderline), can still be developing SACD. MRI spine may show T2 hyperintensity in the dorsal columns, but it may be normal, the finding is not pathognomonic (similar appearances occur in other metabolic, inflammatory, infective or structural disorders), and diagnosis remains clinical and biochemical. Nitrous oxide (laughing gas) abuse is an increasingly common cause of acute SACD in young people — N2O irreversibly oxidises the cobalt in cobalamin from the Co+ active form to the inactive Co3+ form, causing acute functional B12 deficiency that can cause SACD within days to weeks of heavy use. Serum B12 levels may be misleadingly normal — homocysteine and methylmalonic acid are the sensitive functional markers.

Autoimmune gastritis (historically termed pernicious anaemia) is an important irreversible cause of B12 deficiency — an autoimmune condition in which antibodies destroy gastric parietal cells and/or block intrinsic factor (antibody positivity rates vary by assay and population). The condition disproportionately affects: women (2:1 female:male ratio), Northern European populations (particularly Scandinavian), elderly patients (peak incidence in the 6th-7th decade), and patients with other autoimmune conditions (thyroid disease, vitiligo, Addison's disease, type 1 diabetes — polyglandular autoimmune syndrome). The lifelong requirement for B12 injections is the most important management principle — PA patients who stop their B12 injections will develop deficiency again within months because the underlying absorption defect is permanent. GPs who conduct annual medication reviews and consider stopping 'unnecessary' B12 injections in PA patients are at risk of causing iatrogenic SACD. The injection should never be stopped once diagnosed in PA.

The borderline serum B12 grey zone (180–350 ng/L in NICE NG239) is one of the most clinically challenging areas in routine blood test interpretation — approximately 50% of patients with serum B12 in this range have functional intracellular B12 deficiency (demonstrable by elevated homocysteine and/or MMA), while the other 50% have adequate B12 stores. The practical approach for primary care: (1) treat the clinical picture — if the patient has symptoms consistent with B12 deficiency (fatigue, peripheral neuropathy, cognitive change) with borderline B12, consider starting B12 replacement while awaiting MMA (NICE NG239), especially if symptoms could deteriorate rapidly, after gastrectomy, ileal resection or bariatric surgery, or in pregnancy or breastfeeding; (2) arrange functional markers (MMA + homocysteine) if available — elevated levels in a borderline-B12 patient confirm functional deficiency; (3) check folate — isolated folate deficiency also causes elevated homocysteine; (4) the reticulocyte response to the first B12 injection is a useful diagnostic test — a peak reticulocyte count at days 5-7 post-injection confirms that the anaemia was indeed B12-responsive. The maxim in UK practice: 'If in doubt, treat — the treatment is safe and inexpensive.'

The gastric carcinoid risk in pernicious anaemia is clinically important but often omitted from patient education at diagnosis — PA causes chronic achlorhydria (absence of gastric acid due to parietal cell destruction). The loss of acid causes: (1) reflex hypergastrinaemia (antral G cells secrete gastrin attempting to stimulate acid production from the absent parietal cells); (2) sustained hypergastrinaemia is a trophic stimulus for enterochromaffin-like (ECL) cells in the gastric fundus, leading over many years to ECL cell hyperplasia and eventually type I gastric carcinoid tumours. Type I gastric carcinoids are the most benign of the three gastric carcinoid types — they are almost exclusively associated with hypergastrinaemia from PA (or autoimmune atrophic gastritis), are usually small (<1 cm), multiple, and have an extremely low risk of metastasis (<5%). Patients should be reassured that this is not the aggressive gastric cancer that most people fear. Routine population-style surveillance is not currently recommended by NICE; management is symptom- and histology-led, with any surveillance interval set by gastroenterology from the endoscopic and histological findings.

A single gastroscopy at PA diagnosis was historically common practice — it was intended to serve two purposes: exclusion of gastric malignancy (atrophic gastritis from PA carries approximately 1-3% lifetime gastric cancer risk — significantly higher than the general population but still modest) and exclusion of type I gastric carcinoid. NICE NG239 (2024) changed this: routine gastroscopic surveillance is not recommended for everyone with autoimmune gastritis, and gastroscopy should be offered only where there is a clinical reason — in particular new or worsening upper GI symptoms such as dyspepsia, nausea or vomiting, which are then managed through NICE NG12 (updated April 2026). Diagnose autoimmune gastritis on the anti-intrinsic factor antibody with a low B12 (if the anti-intrinsic factor antibody is negative but suspicion remains, NG239 suggests considering anti-gastric parietal cell antibody, gastrin or gastroscopy with gastric-body biopsy; parietal cell antibodies are not diagnostic alone). So the initial management plan is B12 replacement plus a clear symptom-based safety net for endoscopy, not an automatic endoscopy referral.

The debate about injection frequency in pernicious anaemia is one of the most contested areas in UK primary care — the standard schedule (1 mg IM hydroxocobalamin every 2–3 months, BNF) is based on pharmacokinetic data showing that the body can store 2-5 mg of B12, that a 1 mg injection repletes stores, and that stores last approximately 3 months in a healthy person. However, many PA patients and patient advocacy groups (Pernicious Anaemia Society) argue that individual variation in B12 metabolism means that some patients experience return of symptoms (fatigue, neurological symptoms) before the 3-month injection is due. The biochemical argument is sound: serum B12 levels after injection peak at approximately 1 week and fall back to baseline-or-below by 4-8 weeks in many patients, because the excess B12 from the injection is excreted in urine within days — only the B12 that enters cells and is stored there contributes to long-term function. The BNF advises more frequent injections (every 2 months) when there is neurological involvement. For non-neurological PA where patients report early symptom recurrence, a trial of more frequent dosing (every 2 months) with reassessment is reasonable — there is no toxicity risk from more frequent hydroxocobalamin.

The folate-B12 interaction is one of the most important prescribing safety principles in haematology — giving folate alone to a patient with undiagnosed B12 deficiency causing megaloblastic anaemia will partially correct the macrocytic anaemia (because both B12 and folate are needed for the same DNA synthesis pathway, and supplementing one partially compensates for the deficiency of the other), but will not address the neurological B12 deficiency. The result: the macrocytic anaemia improves, the clinician believes the condition is treated, but neurological B12 deficiency progresses unchecked to SACD. This scenario is called 'subacute combined degeneration unmasked by folate treatment' and represents a clinical error. The safe practice: always check serum B12 and folate simultaneously in any patient with macrocytosis or unexplained neurological symptoms. If both are deficient: treat B12 first (or simultaneously with folate) — never treat folate alone without addressing B12 status. The BNF warns that folic acid should never be given alone in B12 deficiency states because it may precipitate subacute combined degeneration — so check B12 before starting folic acid.

The Pernicious Anaemia Society is the most important patient resource for PA management in the UK — it was founded in 2006 by Martyn Hooper after his own delayed PA diagnosis and provides: patient information leaflets, a helpline staffed by trained advisors, support groups across the UK, advocacy for improved diagnostic criteria (the society campaigns for testing functional B12 markers and broadening diagnostic criteria), and a travel card in multiple languages. The society has been instrumental in highlighting the problem of doctors discontinuing B12 injections after patients lose blood test abnormalities — once B12 injections normalise the MCV and the haemoglobin, some doctors query whether injections are still needed. They are — the underlying IF deficiency is permanent and will cause re-depletion within months of stopping. The society's leaflet 'What PA patients wish their GPs knew' is a valuable educational resource. GPs should provide the PA Society website (pernicious-anaemia-society.org) to every newly diagnosed PA patient.

The NICE NG239 (2024) guideline on vitamin B12 deficiency in over 16s provides updated guidance that significantly affects primary care practice — key updates include: (1) urgent treatment and specialist advice for neurological features, with alternate-day IM hydroxocobalamin until no further improvement per the BNF; (2) recommendation for MMA testing when total or active B12 is in the indeterminate range, rather than watchful waiting; (3) acknowledgement that some patients may require more frequent B12 injections based on individual clinical response; (4) specific guidance on oral versus IM treatment for different causes. GPs should be aware that NG239 updates the earlier BSH (BCSH) cobalamin and folate guideline (2014) for adults and represents a significant update in diagnostic criteria and management recommendations. The key clinical message from NG239: treat based on clinical picture + serum B12 + functional markers where available; do not withhold treatment in symptomatic patients with borderline-low B12; ensure patients with neurological manifestations receive more frequent injections.